Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.36 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.35 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.35 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.35 |
| ▸ | BTK | Q06187 | 1/20 | 0.35 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.32 |
| ▸ | CHRNB2 | P17787 | 2/20 | 0.31 |
| ▸ | CHRNA4 | P43681 | 2/20 | 0.31 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.31 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.31 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.31 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | MMP2 | P08253 | 1/20 | 0.31 |
| ▸ | ANPEP | P15144 | 1/20 | 0.31 |
| ▸ | RECQL | P46063 | 1/20 | 0.30 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17883906 | 1.00 | HRH3 (0.39) | HRH3MAPK1CHRM2CHRM1CHRM3 | |
| SCHEMBL17883938 | 1.00 | HRH3 (0.39) | HRH3MAPK1CHRM2CHRM1CHRM3 | |
| Hydrochloric Acid SCHEMBL30660867 | 0.98 | HRH3 (0.38) | HRH3MAPK1CHRM2CHRM1CHRM3 | |
| SCHEMBL18347537 | 0.89 | HRH3 (0.34) | HRH3MAPK1CHRM2CHRM1CHRM3 | |
| SCHEMBL1298062 | 0.86 | HRH3 (0.43) | HRH3MAPK1CHRM2CHRM1CHRM3 | |
| SCHEMBL21169562 | 0.86 | HRH3 (0.40) | HRH3MAPK1CHRM2CHRM1CHRM3 | |
| SCHEMBL17679765 | 0.86 | HRH3 (0.40) | HRH3MAPK1CHRM2CHRM1CHRM3 | |
| SCHEMBL15938511 | 0.83 | BTK (0.44) | HRH3MAPK1CHRM2CHRM1CHRM3 | |
| SCHEMBL3657235 | 0.83 | CHRNB2 (0.38) | HRH3MAPK1CHRM2CHRM1CHRM3 | |
| SCHEMBL15614036 | 0.83 | BTK (0.44) | HRH3MAPK1CHRM2CHRM1CHRM3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4211116-B1 | NOVEL HETEROCYCLIC ANTIBIOTICS | HOFFMANN LA ROCHE (CH) | 2024-08-07 | — | — | EP | disclosed |
| US-20240139158-A1 | METHODS OF TREATING PULMONARY DISEASES AND DISORDERS | PROTEOSTASIS THERAPEUTICS INC (US) | 2024-05-02 | — | — | US | disclosed |
| US-20230265116-A1 | DEGRADATION OF (EGFR) BY CONJUGATION OF EGFR INHIBITORS WITH E3 LIGASE LIGAND AND METHODS OF USE | BEONE MEDICINES I GMBH (CH) | 2023-08-24 | — | — | US | disclosed |
| EP-3237411-B1 | COMPOUNDS, COMPOSITIONS, AND METHODS FOR INCREASING CFTR ACTIVITY | PROTEOSTASIS THERAPEUTICS INC (US) | 2023-06-07 | — | — | EP | disclosed |
| US-20220175735-A1 | METHODS OF TREATING PULMONARY DISEASES AND DISORDERS | PROTEOSTASIS THERAPEUTICS INC (US) | 2022-06-09 | — | — | US | disclosed |
| CN-107207487-B | Compounds, compositions and methods for increasing CFTR activity | 蛋白质平衡治疗股份有限公司 | 2021-12-28 | — | — | CN | disclosed |
| US-20200190072-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS FOR INCREASING CFTR ACTIVITY | PROTEOSTASIS THERAPEUTICS, INC. | 2020-06-18 | — | — | US | disclosed |
| US-20200172546-A1 | PYRAZOLO[3,4-B]PYRAZINE DERIVATIVES AS SHP2 PHOSPHATASE INHIBITORS | RELAY THERAPEUTICS, INC. | 2020-06-04 | — | — | US | disclosed |
| CN-110709402-A | Heteroaryl pyrimidone derivatives, preparation method and medical application thereof | 浙江海正药业股份有限公司 | 2020-01-17 | — | — | CN | disclosed |
| US-10392372-B2 | Compounds, compositions, and methods for increasing CFTR activity | PROTEOSTASIS THERAPEUTICS, INC. (US) | 2019-08-27 | — | — | US | disclosed |
| US-20170369480-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS FOR INCREASING CFTR ACTIVITY | PROTEOSTASIS THERAPEUTICS, INC. | 2017-12-28 | — | — | US | disclosed |
| US-20160235716-A1 | SPIROCYCLIC HAT INHIBITORS AND METHODS FOR THEIR USE | ABBVIE INC. (US) | 2016-08-18 | — | — | US | disclosed |
| WO-2016044770-A1 | SPIROCYCLIC HAT INHIBITORS AND METHODS FOR THEIR USE | ABBVIE INC. (US) | 2016-03-24 | — | — | WO | disclosed |
| US-20150031659-A1 | 1,3,4-OXADIAZOLE AND 1,3,4-THIADIAZOLE BETA-LACTAMASE INHIBITORS | MERCK SHARP & DOHME CORP. | 2015-01-29 | — | — | US | disclosed |
| US-20150031659-A1 | 1,3,4-OXADIAZOLE AND 1,3,4-THIADIAZOLE BETA-LACTAMASE INHIBITORS | MERCK SHARP & DOHME CORP. | 2015-01-29 | — | — | US | disclosed |
| CN-102014914-A | 3H-[1,2,3]triazolo[4,5-D]pyrimidine compounds, their use as MTOR kinase and PI3 kinase inhibitors, and their syntheses | WYETH CORP | 2011-04-13 | — | — | CN | disclosed |
| EP-2252296-A1 | 3H-[1,2,3]TRIAZOLO[4,5-D]PYRIMIDINE COMPOUNDS, THEIR USE AS MTOR KINASE AND PI3 KINASE INHIBITORS, AND THEIR SYNTHESES | Wyeth LLC (US) | 2010-11-24 | — | — | EP | disclosed |
| US-20090298894-A1 | AMINO ACID COMPOUNDS | ASAHI KASEI PHARMA CORPORATION (JP) | 2009-12-03 | — | — | US | disclosed |
| WO-2009091788-A1 | 3H-[1,2,3]TRIAZOLO[4,5-D]PYRIMIDINE COMPOUNDS, THEIR USE AS MTOR KINASE AND PI3 KINASE INHIBITORS, AND THEIR SYNTHESES | WYETH (US) | 2009-07-23 | — | — | WO | disclosed |
| US-20090181963-A1 | 3H-[1,2,3]TRIAZOLO[4,5-D]PYRIMIDINE COMPOUNDS, THEIR USE AS mTOR KINASE AND PI3 KINASE INHIBITORS, AND THEIR SYNTHESES | WYETH (US) | 2009-07-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230265116-A1 | DEGRADATION OF (EGFR) BY CONJUGATION OF EGFR INHIBITORS WITH E3 LIGASE LIGAND AND METHODS OF USE | EGFR, CBL, ERBB2 | HRH3 3390/4885MAPK1 1931/4885CHRM2 4766/4885 |
| US-20160235716-A1 | SPIROCYCLIC HAT INHIBITORS AND METHODS FOR THEIR USE | KAT2B, HDAC1, HDAC9 | HRH3 450/4885MAPK1 2737/4885CHRM2 1376/4885 |
| US-20240139158-A1 | METHODS OF TREATING PULMONARY DISEASES AND DISORDERS | SMPD1, ELANE, SMPD2 | HRH3 378/4885MAPK1 4841/4885CHRM2 27/4885 |
| US-20150031659-A1 | 1,3,4-OXADIAZOLE AND 1,3,4-THIADIAZOLE BETA-LACTAMASE INHIBITORS | BTD, BLVRB, BBOX1 | HRH3 2214/4885MAPK1 3848/4885CHRM2 4209/4885 |
| US-20200172546-A1 | PYRAZOLO[3,4-B]PYRAZINE DERIVATIVES AS SHP2 PHOSPHATASE INHIBITORS | PTPRJ, PTPN2, PTPN5 | HRH3 4514/4885MAPK1 562/4885CHRM2 4686/4885 |
| US-20090181963-A1 | 3H-[1,2,3]TRIAZOLO[4,5-D]PYRIMIDINE COMPOUNDS, THEIR USE AS mTOR KINASE AND PI3 KINASE INHIBITORS, AND THEIR SYNTHESES | MTOR, PIK3CA, PIK3CD | HRH3 1593/4885MAPK1 80/4885CHRM2 4877/4885 |
| US-20170369480-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS FOR INCREASING CFTR ACTIVITY | CFTR, SCNN1B, SCNN1G | HRH3 2818/4885MAPK1 4625/4885CHRM2 2346/4885 |
| US-10392372-B2 | Compounds, compositions, and methods for increasing CFTR activity | CFTR, SCNN1B, SCNN1G | HRH3 2818/4885MAPK1 4625/4885CHRM2 2346/4885 |
| US-20090298894-A1 | AMINO ACID COMPOUNDS | S1PR1, S1PR2, S1PR5 | HRH3 117/4885MAPK1 1118/4885CHRM2 2015/4885 |
| US-20200190072-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS FOR INCREASING CFTR ACTIVITY | CFTR, SCNN1B, SCNN1G | HRH3 2818/4885MAPK1 4625/4885CHRM2 2346/4885 |
| US-20220175735-A1 | METHODS OF TREATING PULMONARY DISEASES AND DISORDERS | SMPD1, ELANE, SMPD2 | HRH3 378/4885MAPK1 4841/4885CHRM2 27/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.